Nephros (NASDAQ:NEPH) Releases Earnings Results

Nephros (NASDAQ:NEPH) released its earnings results on Thursday. The company reported $0.06 EPS for the quarter, Zacks reports. Nephros had a return on equity of 11.03% and a net margin of 8.38%.The firm had revenue of $6.02 million during the quarter, compared to the consensus estimate of $4.99 million.

Here are the key takeaways from Nephros’ conference call:

• Record revenue and broad-based growth: Second-quarter revenue reached $6.0 million, up 36% year over year and 15% sequentially. Programmatic product revenue rose 27%, service revenue nearly tripled, and growth was driven largely by increased sales and services within existing customer sites.
• Profitability improved substantially: Net income increased more than 400% to approximately $1.2 million, while adjusted EBITDA rose 260% to $1.3 million. The company ended the quarter with $4.7 million in cash and no debt.
• Reported margins benefited from a one-time tariff refund: The 67% quarterly gross margin included approximately $600,000 of tariff refunds, about $500,000 of which related to inventory sold in prior periods. Management expects tariff policy, currency movements, shipping costs, and the growing mix of lower-margin services and commercial products to continue pressuring underlying margins.
• New products remain an emerging opportunity rather than a current growth driver: PFAS, microplastics, and nanoplastics offerings have not yet gained significant traction and may require additional education, trials, and regulatory momentum. Education initiatives are currently used to drive product adoption and are not being monetized directly.
• Cash generation weakened: Operating cash flow fell to $681,000 in the second quarter from $994,000 a year earlier, while first-half operations used $990,000 as accounts receivable and inventory increased.

Nephros Trading Up 17.3%

Nephros stock traded up $0.62 during mid-day trading on Friday, hitting $4.21. The company had a trading volume of 67,358 shares, compared to its average volume of 10,920. The company has a market capitalization of $45.72 million, a price-to-earnings ratio of 26.31 and a beta of 1.51. Nephros has a 12-month low of $2.66 and a 12-month high of $6.42. The company’s fifty day moving average is $3.48 and its 200-day moving average is $3.53.

Institutional Trading of Nephros

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC acquired a new stake in shares of Nephros during the 4th quarter valued at about $29,000. Dimensional Fund Advisors LP purchased a new stake in shares of Nephros in the third quarter valued at approximately $64,000. Heron Bay Capital Management acquired a new position in shares of Nephros during the 4th quarter worth approximately $66,000. Citadel Advisors LLC lifted its position in shares of Nephros by 39.2% during the 3rd quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock valued at $78,000 after buying an additional 4,655 shares in the last quarter. Finally, XTX Topco Ltd grew its stake in Nephros by 48.5% in the 4th quarter. XTX Topco Ltd now owns 21,617 shares of the company’s stock valued at $105,000 after acquiring an additional 7,062 shares during the period. Institutional investors and hedge funds own 41.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on NEPH shares. Northland Securities initiated coverage on shares of Nephros in a research note on Friday, July 17th. They set a “market perform” rating and a $4.00 price objective for the company. Zacks Research upgraded shares of Nephros to a “hold” rating in a research note on Monday, July 20th. Finally, Weiss Ratings raised shares of Nephros from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 3rd. Three research analysts have rated the stock with a Hold rating, According to data from MarketBeat, Nephros has an average rating of “Hold” and a consensus price target of $4.00.

About Nephros

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.